Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report:Emergent BioSolutions | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report:Emergent BioSolutions

Revenues climb 55% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions
 
3Q Revenues: $138.0 million (+55%)

3Q Earnings: $21.8 million (+61%)

YTD Revenues: $302.2 million (+41%)

YTD Earnings: $6.6 million (earnings were $15.9 in 3Q13)

Comments: BioThrax sales were $66.0 million, down 5%. Other biodefense revenue was $11.7 million, up 67%. Revenues from contract manufacturing operations, gained with the Cangene acquisition in 1Q14, were $9.4 million. These operations comprise services including biopharma product development, product filling, lyophilization and stability studies. R&D expenses were $44.2 million, up 53% primarily attributable to additional product development programs from the Cangene acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics